Skip to main content
Clinical Trials/NCT04212741
NCT04212741CompletedNot Applicable

Effectiveness of Oral Hyaluronic Acid (A+ HA(tm), TOP Pharm.) in Knee Osteoarthritis: Clinical Trial

China Medical University Hospital1 site in 1 country97 target enrollmentStarted: November 1, 2012Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
97
Locations
1
Primary Endpoint
Knee Injury and Osteoarthritis Outcome Score (KOOS)

Study Overview

Brief Summary

This is a double-blinded, placebo-controlled, randomized trial to assess the efficacy of oral solution of hyaluronic acid mixture (A+ HA(tm)). During 8 weeks treatment period, there were three follow-up visits requested (Week 2, Week 4 and Week 8).

Detailed Description

Subjects were initially screened at the Randomization/Baseline Visit (Week 0). Eligible subjects were randomized at the same visit into treatment period, and received the assigned treatment in a double-blind fashion for 8 weeks. Efficacy was measured by the several questionnaire including Knee injury and Osteoarthritis (KOOS), the Short Form-36 (SF-36) and Pittsburgh Sleep Quality Index (CPSQI) for each visit. Incidences of adverse events (AEs) were monitored for each subject once the subject had received 1 dose of study medication; the incidence of serious AEs (SAEs) were monitored for each subject once the subject had signed the informed consent through to the End-of-Study or ET Visit. Vital signs were measured at baseline and End-of-Study or ET Visit.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
40 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age >= 40 years old
  • •Male or Female
  • •With osteoarthritis of the knee based on the definition of Ahlback 1968 and with significant symptoms within 30 days before enrollment.
  • •No limitation for use of concomitant medication

Exclusion Criteria

  • •Use of Glucosamine within 1 month before enrollment
  • •Osteoarthritis of the knee due to exercise or occupational injury
  • •Allergy with Oral Hyaluronic Acid
  • •Bilateral Total Knee Replacement
  • •Need use wheelchairs
  • •With at least one condition: Known other causes of arthritis (infectious arthritis, rheumatoid arthritis, connective tissue disease, gout, pseudogout, or psoriatic arthritis), bony or soft tissue malignancy or skin lesions or peripheral neuropathy involving the lower extremities, cardiopulmonary disease which limits walking more than knee pain. Knee instability defined as report of knee bucking or locking within the past month of the study knee, major neurologic deficit that affects gait, psychiatric illness that limits informed consent, and parkinsonism.

Arms & Interventions

A+ HA(tm)

Experimental

20 ml oral solution of hyaluronic acid mixture in a bottle. Administration with 250~500 ml water under fasting condition in the morning.

Intervention: A+ HA(tm) (Dietary Supplement)

Placebo

Placebo Comparator

20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.

Intervention: Placebo (Dietary Supplement)

Outcomes

Primary Outcomes

Knee Injury and Osteoarthritis Outcome Score (KOOS)

Time Frame: 8 weeks

A normalized score (0-100, 0 indicating extreme symptoms and 100 indicating no symptoms) was calculated.

Secondary Outcomes

  • Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)(8 weeks)
  • SF-36(8 weeks)
  • Chinese version Pittsburgh Sleep Quality Index (CPSQI)(8 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials